Oral Proteins & Peptides Market

Market Overview The global market for oral proteins and peptides is projected to expand significantly, from USD 1.37 billion in 2025 to USD 2.36 billion by 2031, exhibiting a compound annual growth rate of 9.49%. These therapeutic biologic molecules, including hormones and enzymes, are designed for oral ingestion, offering a non-invasive alternative to conventional injectable treatments. The market's growth is largely driven by the increasing worldwide prevalence of chronic metabolic conditions and the associated need for patient-friendly drug delivery methods that improve treatment adherence. A key factor is the imperative for more effective, pain-free management of long-term diseases, as evidenced by the International Diabetes Federation's 2025 estimate of approximately 589 million adults globally living with diabetes, highlighting the considerable demand for accessible solutions and thus boosting the commercial appeal of oral biologic formulations. However, a major challenge for the market remains the naturally low bioavailability of these large molecules. The gastrointestinal tract's harsh environment, characterized by enzymatic degradation and acidic pH, rapidly breaks down proteins before systemic absorption, making the development of advanced delivery technologies crucial for protecting drugs and ensuring adequate therapeutic uptake to support market expansion. Market Driver The market is being fundamentally transformed by technological breakthroughs in oral protein delivery systems, which are effectively overcoming previous limitations like enzymatic degradation and poor absorption. Advances in permeation enhancers and carrier technologies now enable biologic therapies to achieve therapeutic concentrations comparable to those delivered by subcutaneous injections. For example, a Phase 2 trial in August 2025 by Viking Therapeutics showed that an oral tablet of VK2735 led to an average weight loss of up to 12.2% in patients with metabolic conditions after 13 weeks, demonstrating oral modalities' ability to rival established parenteral treatments and broaden the patient pool. This efficacy also extends to bone health, with Entera Bio reporting a 3.1% increase in lumbar spine bone mineral density from their oral parathyroid hormone candidate EB613 in October 2025. Complementing this, a surge in strategic collaborations and technology licensing deals is rapidly accelerating commercial growth by providing crucial capital and development expertise. Major pharmaceutical companies are increasingly partnering with specialized biotech firms to integrate advanced oral delivery platforms, thereby reducing the significant risks of developing new technologies internally. These partnerships, often involving considerable financial investments, validate the commercial promise of these technologies, such as Rani Therapeutics' October 2025 collaboration with Chugai Pharmaceutical, valued at up to $1.085 billion, for developing oral biologics using the RaniPill capsule. Such high-value agreements highlight the industry's strategic focus on non-invasive delivery, ensuring the swift progression of promising oral biologic candidates from clinical trials to market readiness. Market Challenge The primary impediment to the global oral proteins and peptides market expansion is the naturally low bioavailability of these large molecules due to gastrointestinal instability. The human digestive system's inherent design, with enzymatic activity and acidic pH, efficiently breaks down proteins into amino acids. This harsh environment degrades therapeutic peptides before they can cross the intestinal lining and enter systemic circulation. As a result, pharmaceutical developers encounter high failure rates in clinical trials because achieving consistent therapeutic blood concentrations without invasive delivery methods is exceptionally challenging. This technical hurdle significantly affects the market's commercial path, leading to increased development costs and extended regulatory processes. Investors and manufacturers are frequently dissuaded by the unfavorable risk-to-reward ratio of oral biologic programs compared to established injectable options. The difficulty in gaining regulatory approval for these intricate formulations is underscored by the U.S. FDA's 2025 report, which indicates that the Center for Biologics Evaluation and Research (CBER) approved only 18 new biological treatments, illustrating the ongoing challenges in successfully introducing stable and effective biologic formulations to the market. Market Trends A notable structural shift in the market is the expansion into autoimmune and oncology therapeutic areas, as developers successfully adapt oral peptide technologies for complex inflammatory diseases, moving beyond the traditional focus on metabolic conditions. This trend is marked by the clinical validation of oral receptor antagonists that provide the efficacy of injectable biologics combined with the convenience of a daily pill, thereby addressing critical unmet needs in managing chronic autoimmune conditions. For example, Protagonist Therapeutics reported positive Phase 2b study results in March 2025, where the oral peptide icotrokinra achieved a 63.5% clinical response rate in patients with moderately to severely active ulcerative colitis, demonstrating oral modalities' strong potential in high-value therapeutic categories. Simultaneously, the emergence of ingestible robotic pill technologies is introducing a mechanical delivery method that surpasses the limitations of chemical permeation enhancers. These device-based formulations are engineered to physically inject macromolecules into the intestinal wall, thereby overcoming the volume constraints often encountered in traditional oral biologic development. This innovative approach facilitates the administration of significantly larger drug volumes, making it possible to deliver complex proteins that require higher dosages. Biora Therapeutics, in March 2025, announced that its BioJet platform can deliver payloads exceeding 300 microliters, a technical capability that allows these devices to manage therapeutic loads previously restricted to parenteral delivery. Key Market Players * AbbVie Inc. * Merck & Co Inc * Pfizer Inc * Novo Nordisk A/S * Hoffmann-La Roche Inc * Sanofi SA * AstraZeneca PLC * Bristol-Myers Squibb Co * Tarsa Therapeutics Inc * Novartis AG Report Scope In this report, the Global Oral Proteins & Peptides Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below: # Oral Proteins & Peptides Market, By Drug Type * Calcitonin * Insulin * Linaclotide * Octreotide * Plecanatide # Oral Proteins & Peptides Market, By Application * Bone Diseases * Diabetes * Gastric & Digestive Disorders * Hormonal Disorders # Oral Proteins & Peptides Market, By Region * North America United States Canada Mexico * Europe France United Kingdom Italy Germany Spain * Asia Pacific China India Japan Australia South Korea * South America Brazil Argentina Colombia * Middle East & Africa South Africa Saudi Arabia UAE Competitive Landscape Company Profiles: Detailed analysis of the major companies present in the Global Oral Proteins & Peptides Market. Available Customizations: Global Oral Proteins & Peptides Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: Company Information * Detailed analysis and profiling of additional market players (up to five).